Drug Trial Radar · NCT00312377
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,690
Actual
Start
May 2006
Primary completion
Aug 2008
Study completion Mar 2014
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.
Conditions
- Non-small Cell Lung Cancer
- Lung Cancer
Interventions
DocetaxelDrug
infusion
VandetanibDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) in the Overall PopulationTime frame: RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
- Progression-Free Survival (PFS) in the Female PopulationTime frame: RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
Locations
156 sites in 25 countries. Site status is shown where the registry gives one.
Research Site
Fullerton, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Colorado Springs, Colorado
Research Site
Norwalk, Connecticut
Research Site
Ocala, Florida
Research Site
Marietta, Georgia
Research Site
Joliet, Illinois
Research Site
Park Ridge, Illinois
Research Site
Hutchinson, Kansas
Research Site
Louisville, Kentucky
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
St Louis, Missouri
Research Site
Henderson, Nevada
Research Site
Albany, New York
Research Site
Armonk, New York
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Hickory, North Carolina
Research Site
Portland, Oregon
Research Site
Austin, Texas
Research Site
Houston, Texas
Research Site
Ogden, Utah
Research Site
Alexandria, Virginia
Research Site
Salem, Virginia
Research Site
Vancouver, Washington
Research Site
Bahía Blanca, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Mendoza, Argentina
Research Site
Rosario, Argentina
Research Site
Graz, Austria
Research Site
Grimmenstein, Austria
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Wels, Austria
Research Site
Brussels (Jette), Belgium
Research Site
Brussels (Woluwé-St-Lambert), Belgium
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.